| Overview |
| bsm-90271r-50µL |
| IL13 receptor alpha 1 Recombinant Antbody Kit (KD-Validated) |
| WB, FCM, IC |
| Knockdown Validated |
| Human |
| Specifications |
| Unconjugated |
| Rabbit |
| A synthesized peptide derived from human IL13 receptor alpha 1 |
| 50-101/427 |
| Recombinant |
| IgG |
| Lot dependent |
| Affinity Purified |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| -20 °C |
| Target |
| 3597 |
| P78552 |
| IL13RA1; Interleukin 13 Receptor Subunit Alpha 1; CD213a1 Antigen; IL-13Ra; CD213a1; NR4; Interleukin-13 Receptor Subunit Alpha-1; Interleukin 13 Receptor Alpha 1; IL-13 Receptor Subunit Alpha-1; IL13 Receptor Alpha-1 Chain; Cancer/Testis Antigen 19; IL-13R Subunit Alpha-1; CT19; IL-13R-Alpha-1; IL-13RA1; IL13RA; IL13R |
| Cell Line: Hela Knockdown technology: shRNA Knockdown |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IC |
1:1000 |
Powered by Bioz